Shares in Triangle-based Salix Pharmaceuticals (Nasdaq: SLXP) fell 10 percent Monday after the FDA raised new concerns about possible additional use of one of its products.

Salix wants to expand use of its bowel drug Xifaxan.

“Issues were raised in the documents we were not aware of,” said Jefferies & Co. analyst Corey Davis. He said the panel seems unexpectedly skeptical about the Xifaxan as an IBS treatment, although he thinks the drug will ultimately be approved, The Associated Press noted.

Salix is scheduled to meet with the FDA on Wednesday.

Shares fell $3.66 to close at $33.85.

Read more from The AP here.

Get the latest news alerts: Follow LTW at Twitter.